-

QIAGEN Announces Preliminary Q1 2020 Results

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales and adjusted earnings per share results for the first quarter of 2020.

Net sales rose approximately 9% at constant exchange rates (CER) compared to the outlook for the first quarter announced on February 4, 2020, for approximately 2-3% CER growth. Sales results reflected very significant demand for solutions used in COVID-19 pandemic testing against weaker customer demand trends in other product areas. Adjusted earnings per share (EPS) are expected to be about $0.34-0.35 CER based on preliminary results compared to the outlook for the first quarter for approximately $0.28-0.29 CER.

Based on actual exchange rates as of March 31, 2020, QIAGEN expects currency movements against the U.S. dollar (reporting currency) to have an adverse impact on results for the first quarter of 2020 of about two percentage points on net sales at actual rates, and resulting in an adverse impact of up to $0.01 per share on adjusted EPS.

Further information will be provided when QIAGEN reports full results for the first quarter of 2020 in early May 2020.

Contacts

QIAGEN
Investor Relations
John Gilardi
+49 2103 29 11711
Phoebe Loh
+49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer
+49 2103 29 11826
Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com

Industry:

QIAGEN

FWB:QIA
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)
Release Summary
QIAGEN announces preliminary Q1 2020 results
Release Versions
EnglishGerman
$Cashtags
$QGEN
$QIA

Contacts

QIAGEN
Investor Relations
John Gilardi
+49 2103 29 11711
Phoebe Loh
+49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer
+49 2103 29 11826
Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com

Social Media Profiles
QIAGEN Facebook
More News From QIAGEN

Qiagen Announces Form 20-F Annual Report Filing for 2025 Results

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here. QIAGEN will provide printed copies of the 2025 Annual Report to shareholders free of charge upon request. To obtain a printed copy of th...

QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-risk populations. The announcement is being made in time for World TB Day to underscore the continued importance of improving TB detection and prevention glo...

QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndromic testing system. With this milestone, laboratories can run both QIAstat-Dx Respiratory and QIAstat-Dx GI panels on QIAstat-Dx Rise, the high-throughput version of the QIAstat-Dx system. Both versions support compr...
Back to Newsroom